
Liqiang Wei

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7882220/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Autologous hematopoietic stem cell transplantation may improve long-term outcomes in patients with newly diagnosed extranodal natural killer/T-cell lymphoma, nasal type: a retrospective controlled study in a single center. International Journal of Hematology, 2018, 107, 98-104.	0.7	16
2	Prediction of the response of ocular adnexal lymphoma to chemotherapy using combined pretreatment dynamic contrast-enhanced and diffusion-weighted MRI. Acta Radiologica, 2016, 57, 1490-1496.	0.5	10
3	Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis. Journal of Cancer Research and Clinical Oncology, 2021, 147, 863-869.	1.2	10
4	Long-term outcomes of patients treated with an EPOCHL regimen as first-line chemotherapy for newly diagnosed extranodal natural killer/T-cell lymphoma: a retrospective single-center study. Leukemia and Lymphoma, 2020, 61, 337-343.	0.6	7
5	Outcomes of patients treated with SVILE <i>vs</i> . P-GemOx for extranodal natural killer/T-cell lymphoma, nasal type: a prospective, randomized controlled study. Cancer Biology and Medicine, 2020, 17, 795-804.	1.4	2
6	Treatment outcomes and prognostic analysis of elderly patients with extranodal natural killer/T-cell lymphoma, nasal type: a retrospective analysis. Leukemia and Lymphoma, 2020, 61, 2962-2968.	0.6	1
7	SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type. Leukemia Research, 2020, 96, 106422.	0.4	1
8	CD56-Negative Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Study in 443 Patients Treated by Chemotherapy With or Without Asparaginase. Frontiers in Immunology, 2022, 13, 829366.	2.2	1